Zero Candida Technologies (TSXV:ZCT) EBIT: C$-1.03 Mil (TTM As of Dec. 2025)

What is Zero Candida Technologies EBIT?

Zero Candida Technologies TSXV:ZCT 14 EBIT is C$-1.03 Mil as of Dec. 2025. GuruFocus rates TSXV:ZCT with a GF Score™ of 14/100. The stock has 1 warning sign investors should review.

Zero Candida Technologies's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was C$-0.26 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was C$-1.03 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Zero Candida Technologies's annualized ROC % for the quarter that ended in Dec. 2025 was -3,368.00%. Zero Candida Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -2,991.30%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Zero Candida Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -127.32%.

Zero Candida Technologies (TSXV:ZCT) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Zero Candida Technologies's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

	ROC % (Q: Dec. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2025 )	+	Invested Capital (Q: Dec. 2025 ))	/ count )
=	-1.684 * ( 1 - 0% )	/	( (0.031	+	0.069)	/ 2 )
=	-1.684	/	0.05
=	-3,368.00 %

where

	Invested Capital		(Q: Sep. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	2.595	-	0.928	-	( 2.517	-	max(0, 0.937	-	2.573	+	2.517	))
=	0.031

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	2.447	-	1.035	-	( 2.241	-	max(0, 1.057	-	2.4	+	2.241	))
=	0.069

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Zero Candida Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2025 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2025		Q: Dec. 2025
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-1.032	/	( ( (0.022 + max(-0.928, 0))	+	(0.047 + max(-1.002, 0)) )	/	2 )
=	-1.032	/	( ( 0.022	+	0.047 )	/	2 )
=	-1.032	/	0.0345
=	-2,991.30 %

where Working Capital is:

	Working Capital		(Q: Sep. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(0.928	+	0	+	0)
=	-0.928

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.033)	-	(1.035	+	0	+	0)
=	-1.002

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Zero Candida Technologies's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2025 )
	=	-1.03	/	0.809
	=	-127.32 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zero Candida Technologies EBIT Related Terms

Zero Candida Technologies EBIT Historical Data

* Premium members only.

The historical data trend for Zero Candida Technologies's EBIT can be seen below:

Zero Candida Technologies EBIT Chart

Zero Candida Technologies Annual Data

Trend

Jul23

Jul24

Dec25

EBIT

-0.01

-1.03

Zero Candida Technologies Quarterly Data
	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Mar25	Jun25	Sep25	Dec25
EBIT	Get a 7-Day Free Trial							-0.01	-0.31	-0.28	-0.19	-0.26

TSXV:ZCT vs ABT, SYK, MDT: EBIT Comparison

For the Medical Devices subindustry, Zero Candida Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zero Candida Technologies EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Zero Candida Technologies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Zero Candida Technologies's EV-to-EBIT falls into.

Save Embed

14GF Score

Zero Candida Technologies Inc TSXV:ZCT

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Zero Candida Technologies EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-1.03 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of C$-1.03 Mil mean?

Zero Candida Technologies (TSXV:ZCT) has a EBIT of C$-1.03 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Zero Candida Technologies.

Is Zero Candida Technologies' EBIT too high?

Zero Candida Technologies' current EBIT is C$-1.03 Mil. Overall, Zero Candida Technologies has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.

How does Zero Candida Technologies' EBIT compare to ABT and SYK?

Zero Candida Technologies' EBIT of C$-1.03 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Medical Devices & Instruments company?

A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Zero Candida Technologies. Zero Candida Technologies's current EBIT is C$-1.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Zero Candida Technologies stock overvalued right now?

Zero Candida Technologies (TSXV:ZCT) has a current EBIT of C$-1.03 Mil. The current EBIT is C$-1.03 Mil. Zero Candida Technologies' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Zero Candida Technologies (TSXV:ZCT), the current EBIT is C$-1.03 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zero Candida Technologies Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies TSXV:THRM TSXV:NGMD TSXV:IDL TSXV:VER.H XCNQ:ASTI TSXV:TEST.H XCNQ:QAI TSXV:FREQ TSXV:PAIN TSXV:VVTM ABT SYK MDT BSX EW XTER:SHL GEHC DXCM XAMS:PHIA SZSE:300760

Address 666 Burrard Street, Suite 500, Vancouver, BC, CAN, V6C 3P6

Website https://www.zero-candida.com

Zero Candida Technologies Inc is engaged in providing female healthcare solutions. The company technology uses a controlled Blue Light to destroy the fungus at record speed and without side effects. It focused on developing and commercializing several patents and patent applications concerning an AI smart tampon-like device, designed to treat Candidiasis and transfer medical information via Wi-Fi to the doctor.

14GF Score

Get the complete analysis for TSXV:ZCT

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.16

Price

View TSXV:ZCT Analysis

See EBIT data for all stocks →